Company news: Merck, Millennium, Novo Nordisk and Genentech

Share this article:

Merck can update its Vytorin label with data suggesting a cardiovascular benefit in patients with kidney disease, the drugmaker said, but may not claim a new indication. That was the FDA's decision, despite a unanimous vote by an advisory panel in favor of the pre-dialysis outcome. The vote had followed release of data from the SHARP trial, in which Vytorin (ezetimibe/simvastatin) reduced major vascular events in patients with moderate-to-severe chronic kidney disease (CKD). The FDA permitted no such label update for Vytorin's LDL-lowering cousin, Zetia (ezetimibe).

Biotechs made a showing in Fortune Magazine's list of 100 Best Companies to Work For, starting with Millennium: The Takeda Oncology Company, which placed at 35 and was followed closely by Novo Nordisk at 43. Genentech was No. 68.

Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.